

# Andrew B Kneebone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6046488/publications.pdf>

Version: 2024-02-01

98  
papers

3,963  
citations

172207

29  
h-index

123241

61  
g-index

98  
all docs

98  
docs citations

98  
times ranked

4070  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective Comparison of <sup>18</sup> F-Fluoromethylcholine Versus <sup>68</sup> Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1185-1190.	2.8	516
2	The Impact of <sup>68</sup> Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 82-88.	2.8	281
3	<sup>68</sup> Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. <i>BJU International</i> , 2016, 117, 732-739.	1.3	239
4	Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. <i>Lancet</i> , The, 2020, 396, 1422-1431.	6.3	224
5	Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG Tj ETQq1 1 0.784314 rgBT /Overlock). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 21, 1331-1340.	5.1	197
6	Post-prostatectomy radiation therapy: Consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. <i>Radiotherapy and Oncology</i> , 2008, 88, 10-19.	0.3	174
7	Treatment Outcomes from <sup>68</sup> Ga-PSMA PET/CT-“Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1972-1976.	2.8	149
8	Anatomic Boundaries of the Clinical Target Volume (Prostate Bed) After Radical Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1090-1099.	0.4	146
9	The first clinical implementation of electromagnetic transponder-“guided MLC tracking. <i>Medical Physics</i> , 2014, 41, 020702.	1.6	137
10	Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial <sup>68</sup> Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. <i>Journal of Nuclear Medicine</i> , 2019, 60, 950-954.	2.8	133
11	Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. <i>European Urology Oncology</i> , 2018, 1, 531-537.	2.6	106
12	A phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy “ Adjuvant Versus Early Salvage (RAVES) trial. <i>BJU International</i> , 2014, 113, 7-12.	1.3	104
13	Kilovoltage Intrafraction Monitoring for Prostate Intensity Modulated Arc Therapy: First Clinical Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e655-e661.	0.4	94
14	3-Year Freedom from Progression After <sup>68</sup> Ga-PSMA PET/CT-“Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 866-872.	2.8	86
15	The first clinical treatment with kilovoltage intrafraction monitoring (KIM): A real-time image guidance method. <i>Medical Physics</i> , 2015, 42, 354-358.	1.6	71
16	Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 114-124.	3.7	64
17	Follicular Lymphoma Showing Avid Uptake on <sup>68</sup> Ga PSMA-HBED-CC PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 500-501.	0.7	62
18	Multileaf Collimator Tracking Improves Dose Delivery for Prostate Cancer Radiation Therapy: Results of the First Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1141-1147.	0.4	61

#	ARTICLE	IF	CITATIONS
19	The first clinical implementation of real-time image-guided adaptive radiotherapy using a standard linear accelerator. <i>Radiotherapy and Oncology</i> , 2018, 127, 6-11.	0.3	54
20	Real-Time 3D Image Guidance Using a Standard LINAC: Measured Motion, Accuracy, and Precision of the First Prospective Clinical Trial of Kilovoltage Intrafraction Monitoringâ€“Guided Gating for Prostate Cancer Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1015-1021.	0.4	48
21	Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> , 2020, 10, e136-e146.	1.1	41
22	Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial. <i>BMC Cancer</i> , 2017, 17, 180.	1.1	39
23	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.	0.3	39
24	Delineating biochemical failure with 68Ga-PSMA-PET following definitive external beam radiation treatment for prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 99-102.	0.3	38
25	Interim Results of a Prospective Prostate-Specific Membrane Antigen-Directed Focal Stereotactic Reirradiation Trial for Locally Recurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1172-1178.	0.4	36
26	Prostate cancer survivorship essentials framework: guidelines for practitioners. <i>BJU International</i> , 2021, 128, 18-29.	1.3	35
27	Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 530-538.	0.4	33
28	Imageâ€“guided doseâ€“escalated intensityâ€“modulated radiation therapy for prostate cancer: treating to doses beyond 78â€“Gy. <i>BJU International</i> , 2012, 109, 1655-1660.	1.3	32
29	Feasibility of and rectal dosimetry improvement with the use of Space<scp>OAR</scp>Â® hydrogel for doseâ€“escalated prostate cancer radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 511-516.	0.9	31
30	Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: a comparative study. <i>Radiation Oncology</i> , 2015, 10, 215.	1.2	31
31	<sup>68</sup>Gaâ€“PSMAâ€“PET/CT staging prior to definitive radiation treatment for prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 343-346.	0.7	30
32	The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?. <i>Cancers</i> , 2021, 13, 4824.	1.7	29
33	Prostate bed motion may cause geographic miss in postâ€“prostatectomy imageâ€“guided intensityâ€“modulated radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 725-732.	0.9	27
34	Delineating sites of failure following post-prostatectomy radiation treatment using 68 Ga-PSMA-PET. <i>Radiotherapy and Oncology</i> , 2018, 126, 244-248.	0.3	27
35	A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial. <i>Implementation Science</i> , 2018, 13, 43.	2.5	26
36	The impact of rectal and bladder variability on target coverage during post-prostatectomy intensity modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 245-250.	0.3	23

#	ARTICLE	IF	CITATIONS
37	Initial experience with intra-fraction motion monitoring using Calypso guided volumetric modulated arc therapy for definitive prostate cancer treatment. <i>Journal of Medical Radiation Sciences</i> , 2017, 64, 25-34.	0.8	22
38	Big Data Readiness in Radiation Oncology: An Efficient Approach for Relabeling Radiation Therapy Structures With Their TG-263 Standard Name in Real-World Data Sets. <i>Advances in Radiation Oncology</i> , 2019, 4, 191-200.	0.6	22
39	Electromagnetic-Guided MLC Tracking Radiation Therapy for Prostate Cancer Patients: Prospective Clinical Trial Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 387-395.	0.4	21
40	Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2019, 140, 68-75.	0.3	20
41	Australian & New Zealand Faculty of Radiation Oncology Genito-Urinary Group: 2011 consensus guidelines for curative radiotherapy for urothelial carcinoma of the bladder. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 18-30.	0.9	18
42	Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour. <i>Clinical Oncology</i> , 2019, 31, 108-114.	0.6	18
43	Clinician-led improvement in cancer care (CLICC) - testing a multifaceted implementation strategy to increase evidence-based prostate cancer care: phased randomised controlled trial - study protocol. <i>Implementation Science</i> , 2014, 9, 64.	2.5	17
44	A randomised controlled trial evaluating the utility of a patient Decision Aid to improve clinical trial (RAVES 08.03) related decision-making. <i>Radiotherapy and Oncology</i> , 2017, 125, 124-129.	0.3	17
45	The accuracy and precision of Kilovoltage Intrafraction Monitoring (KIM) six degree-of-freedom prostate motion measurements during patient treatments. <i>Radiotherapy and Oncology</i> , 2018, 126, 236-243.	0.3	17
46	Determining optimal planning target volume and image guidance policy for post-prostatectomy intensity modulated radiotherapy. <i>Radiation Oncology</i> , 2015, 10, 151.	1.2	15
47	The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical Review. <i>Cancers</i> , 2021, 13, 2353.	1.7	15
48	Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review. <i>Frontiers in Oncology</i> , 2021, 11, 706331.	1.3	15
49	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. <i>American Journal of Surgical Pathology</i> , 2021, 45, 394-404.	2.1	15
50	The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial. <i>Medical Physics</i> , 2019, 46, 4725-4737.	1.6	14
51	Results of a Prospective Dose Escalation Study of Linear Accelerator-Based Virtual Brachytherapy (BOOSTER) for Prostate Cancer; Virtual HDR Brachytherapy for Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 623-630.	0.6	14
52	Knowledge, attitudes and beliefs towards management of men with locally advanced prostate cancer following radical prostatectomy: an Australian survey of urologists. <i>BJU International</i> , 2016, 117, 35-44.	1.3	13
53	Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans-Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 390-398.	0.9	13
54	Health-related quality of life using intensity-modulated radiation therapy for post-prostatectomy radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2013, 57, 89-96.	0.9	12

#	ARTICLE	IF	CITATIONS
55	Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 1045-1051.	0.4	11
56	Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and <scp>European Association of Urology</scp> biochemical recurrence risk groups. <i>BJU International</i> , 2022, 130, 32-39.	1.3	11
57	Using individual patient anatomy to predict protocol compliance for prostate intensity-modulated radiotherapy. <i>Medical Dosimetry</i> , 2016, 41, 70-74.	0.4	10
58	Factors Affecting Whether Or Not Cancer Patients Consider Using Acupuncture. <i>Acupuncture in Medicine</i> , 2017, 35, 107-113.	0.4	10
59	Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial. <i>Radiotherapy and Oncology</i> , 2020, 151, 234-241.	0.3	10
60	Introducing Computed Tomography Simulation- Free and Electronic Patient-Reported Outcomes- Monitored Palliative Radiation Therapy into Routine Care: Clinical Outcomes and Implementation Experience. <i>Advances in Radiation Oncology</i> , 2021, 6, 100632.	0.6	10
61	Volumetric-modulated arc therapy in postprostatectomy radiotherapy patients: A planning comparison study. <i>Medical Dosimetry</i> , 2013, 38, 262-267.	0.4	9
62	Acupuncture in Oncology: The Effectiveness of Acupuncture May Not Depend on Needle Retention Duration. <i>Integrative Cancer Therapies</i> , 2018, 17, 458-466.	0.8	9
63	Investigation of an adaptive treatment regime for prostate radiation therapy. <i>Practical Radiation Oncology</i> , 2015, 5, e23-e29.	1.1	8
64	Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2543-2550.	0.5	8
65	Early Outcomes and Decision Regret Using PSMA/MRI-Guided Focal Boost for Prostate Cancer SBRT. <i>Practical Radiation Oncology</i> , 2022, 12, e201-e206.	1.1	8
66	Australian prostate-specific antigen outcome and toxicity following radiation therapy for localized prostate cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2003, 47, 422-427.	0.6	7
67	A class solution for volumetric-modulated arc therapy planning in postprostatectomy radiotherapy. <i>Medical Dosimetry</i> , 2014, 39, 261-265.	0.4	7
68	Developing knowledge-based planning for gynaecological and rectal cancers: a clinical validation of RapidPlan. <i>Journal of Medical Radiation Sciences</i> , 2020, 67, 217-224.	0.8	7
69	<scp>FROGG</scp> high-risk prostate cancer workshop: Patterns of practice and literature review. Part II post-radical prostatectomy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 392-400.	0.9	6
70	Quantification of intrafraction prostate motion and its dosimetric effect on VMAT. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2017, 40, 317-324.	1.4	6
71	Acute Epithelial Toxicity Is Prognostic for Improved Prostate Cancer Response to Radiation Therapy: A Retrospective, Multicenter, Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 957-963.	0.4	5
72	Implementing daily soft tissue image guidance with reduced margins for post-prostatectomy radiotherapy: research-based changes to clinical practice. <i>Journal of Medical Radiation Sciences</i> , 2019, 66, 259-268.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy. <i>Radiation Oncology</i> , 2021, 16, 20.	1.2	5
74	Quality of life (QoL) in patients with malignant dysphagia: An international randomized trial comparing radiotherapy alone (RT) versus chemoradiotherapy (CRT)â€”TROG03.01 NCICCTG ES2.. <i>Journal of Clinical Oncology</i> , 2014, 32, 163-163.	0.8	5
75	Re: Andrew J. Stephenson, Michel Bolla, Alberto Briganti, et al. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2012;61:443â€”51. <i>European Urology</i> , 2012, 62, e99.	0.9	4
76	Changing attitudes towards management of men with locally advanced prostate cancer following radical prostatectomy: A follow-up survey of Australia-based urologists. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 744-755.	0.9	4
77	Knowledge, attitudes and decision-making preferences of men considering participation in the TROG RAVES Prostate Cancer Trial (TROG 08.03). <i>Radiotherapy and Oncology</i> , 2016, 119, 84-90.	0.3	4
78	Is radiotherapy the work of the devil?. <i>BJU International</i> , 2018, 121, 6-7.	1.3	4
79	FROGG patterns of practice survey and consensus recommendations on radiation therapy for MIBC. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 882-893.	0.9	4
80	Urologistsâ€™ referral and radiation oncologistsâ€™ treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 134-143.	0.9	4
81	Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. <i>Case Reports in Oncology</i> , 2018, 11, 756-762.	0.3	3
82	Assessing ISUP prostate cancer grade groups in patients treated with definitive dose escalated external beam radiation. <i>Radiotherapy and Oncology</i> , 2021, 162, 91-97.	0.3	3
83	Definition and visualisation of regions of interest in post-prostatectomy image-guided intensity modulated radiotherapy. <i>Journal of Medical Radiation Sciences</i> , 2014, 61, 166-175.	0.8	2
84	The importance of prostate bed tilt during postprostatectomy intensity-modulated radiotherapy. <i>Medical Dosimetry</i> , 2014, 39, 235-241.	0.4	2
85	Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 116-123.	0.9	2
86	What is optimal timing of post prostatectomy radiotherapy? Is adjuvant radiotherapy equivalent to early salvage radiotherapy? The â€œRAVESâ€”phase III randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4690-TPS4690.	0.8	2
87	A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4009-4009.	0.8	2
88	Contemporary salvage post prostatectomy radiotherapy: Early implementation improves biochemical control. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 240-247.	0.9	1
89	A simple algorithm to predict non-compliance with organ at risk dose-volume constraints when planning intensity modulated post-prostatectomy radiation treatment: â€œWhy we should put the CART before the horseâ€”. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 546-551.	0.9	1
90	Salvage Treatment for Biochemical Failure After Radical Prostatectomy: Do We Now Have the Answers?. <i>European Urology</i> , 2020, 77, 699-700.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, TPS4172-TPS4172.	0.8	1
92	Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. Physics and Imaging in Radiation Oncology, 2022, 22, 91-97.	1.2	1
93	Enduring complete metabolic response in metastatic adenocarcinoma of the gastro-oesophageal junction. Oxford Medical Case Reports, 2014, 2014, 105-106.	0.2	0
94	Postoperative radiotherapy in prostate cancer – Authors' reply. Lancet, The, 2021, 397, 1624.	6.3	0
95	Prostate adenocarcinoma with mucinous features – is it PSMA avid?. Journal of Medical Imaging and Radiation Oncology, 2021, , .	0.9	0
96	Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre.. Journal of Clinical Oncology, 2017, 35, 395-395.	0.8	0
97	A phase II, open-label study of durvalumab in combination with stereotactic body radiotherapy in androgen-intact patients with oligometastatic prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS263-TPS263.	0.8	0
98	Don't throw the baby out with the bath water. Prostate, 2022, 82, 397-398.	1.2	0